Today: 3 March 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Aditxt (ADTX) Stock on December 5, 2025: BitXbio Pivot, Reverse Split and Survival Risk Explained

Aditxt (ADTX) Stock on December 5, 2025: BitXbio Pivot, Reverse Split and Survival Risk Explained

Aditxt (NASDAQ: ADTX) traded around $3 per share midday December 5, 2025, with a market cap near $1.7 million and only 559,000 shares outstanding. The company reported $2,770 in revenue and a $37.6 million net loss for the first nine months of 2025, holding $163,041 in cash as of September 30. ADTX faces ongoing Nasdaq delisting risk after a 1-for-113 reverse split. Trading remains volatile with heavy short interest.
5 December 2025
··
Smith & Wesson (SWBI) Stock Soars After Q2 2026 Earnings: Dividend, Outlook and Forecasts as of December 5, 2025

Smith & Wesson (SWBI) Stock Soars After Q2 2026 Earnings: Dividend, Outlook and Forecasts as of December 5, 2025

Smith & Wesson shares surged about 19% to $10.64 on Friday after fiscal Q2 2026 results beat profit forecasts and showed strong cash flow. Net sales for the quarter fell 3.9% to $124.7 million, while adjusted EPS of $0.04 doubled consensus estimates. The stock remains 23% below its 52-week high despite today’s rally.
5 December 2025
····
Paramount Skydance Stock (PSKY): Outlook After Netflix’s Warner Bros. Deal – December 5, 2025

Paramount Skydance Stock (PSKY): Outlook After Netflix’s Warner Bros. Deal – December 5, 2025

Netflix agreed to acquire Warner Bros. Discovery’s studio and streaming businesses for about $72 billion in equity, sidelining Paramount Skydance from the bidding. Paramount Skydance shares fell 6.1% to $13.92 in late morning trading December 5, leaving its market cap near $15.3 billion. The stock is down sharply this week after an earnings miss and the failed Warner Bros. bid.
5 December 2025
····
Protara Therapeutics (TARA) Stock Plunges After $75 Million Offering: Latest Trial Data, Analyst Targets and Outlook as of December 5, 2025

Protara Therapeutics (TARA) Stock Plunges After $75 Million Offering: Latest Trial Data, Analyst Targets and Outlook as of December 5, 2025

Protara Therapeutics shares fell about 21% to $5.44 on December 5 after pricing a $75 million public stock offering at $5.75 per share, increasing the share count by roughly 34%. Trading volume surged to 4.8 million shares, well above recent averages. The company’s market cap stood near $260 million, with institutional holders owning nearly 79%. The offering is expected to close on or about December 8.
5 December 2025
·
Applied Digital (APLD) Stock on December 5, 2025: AI Factory Boom, $16 Billion+ Leases and a New Debt Rating

Applied Digital (APLD) Stock on December 5, 2025: AI Factory Boom, $16 Billion+ Leases and a New Debt Rating

Fitch assigned a ‘BB-’ rating to senior secured notes issued by an Applied Digital subsidiary, citing both growth and credit risk. Applied Digital shares traded around $30.56 on December 5, up over 200% year-to-date, with market cap near $9 billion and a beta close to 7. The company holds $16 billion in long-term AI data-center contracts.
5 December 2025
···
Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025

Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025

Biomea Fusion shares rose over 10% Friday after the company reported 52-week Phase II data showing its experimental diabetes drug icovamenib sustained HbA1c reductions months after treatment ended. The results, presented at WCIRDC in Los Angeles, included no serious treatment-related adverse events. Despite the gain, Biomea’s stock remains down about 80% over the past year.
5 December 2025
··
Argan, Inc. (AGX) Stock Plunges After Record-Backlog Q3: What Today’s Selloff Means for Investors

Argan, Inc. (AGX) Stock Plunges After Record-Backlog Q3: What Today’s Selloff Means for Investors

Argan, Inc. shares plunged about 15% to $302 in Friday morning trading after Q3 fiscal 2026 results showed an EPS beat but missed revenue estimates. The company reported record backlog near $3.0 billion and improved margins, but analysts downgraded the stock and insiders sold over $29 million in shares in the past 90 days. Argan holds no debt and $727 million in cash.
5 December 2025
·
Comcast Stock (CMCSA) Rises as Versant Spin-Off Nears: Latest News, Analyst Targets, and 2026 Outlook

Comcast Stock (CMCSA) Rises as Versant Spin-Off Nears: Latest News, Analyst Targets, and 2026 Outlook

Comcast shares traded at $27.81 midday Friday, up 2.2%, after the board approved the Versant Media Group spin-off. The stock remains well below its 52-week high of $43.30 and is down 13% over the past year, underperforming the S&P 500. Comcast shareholders will receive one Versant share for every 25 Comcast shares held, with the spin-off distribution set for January 2, 2026.
5 December 2025
··
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines shares jumped nearly 40% intraday on December 5 after its pivotal epilepsy trial was stopped early for efficacy and the company reported a positive pre-NDA meeting with the FDA for its essential tremor drug. By late morning, PRAX traded around $265–266, hitting a new 52-week high and pushing its market cap above $1.1 billion. The stock is up over 200% year-to-date.
5 December 2025
·
MP Materials Stock (NYSE: MP): Morgan Stanley Upgrade, Saudi JV and a 41% Pullback – December 5, 2025 Update

MP Materials Stock (NYSE: MP): Morgan Stanley Upgrade, Saudi JV and a 41% Pullback – December 5, 2025 Update

MP Materials shares traded at $62.90 on December 5, up 1.8% after Morgan Stanley upgraded the stock to Overweight with a $71 target. The stock is down 41% from its 2025 peak near $100 but remains up over 270% year-to-date. Analyst targets mostly cluster between $70 and $80, though some models suggest fair value is closer to $46. Trading volume surged following renewed analyst optimism.
5 December 2025
·
Sensei Biotherapeutics (SNSE) Stock: Wild Volatility After Solnerstotug Shutdown and Strategic Review – Price, News and 2025–2026 Forecast

Sensei Biotherapeutics (SNSE) Stock: Wild Volatility After Solnerstotug Shutdown and Strategic Review – Price, News and 2025–2026 Forecast

Sensei Biotherapeutics shares closed at $10.56 on December 4, 2025, up 21%, then surged to $17.20 after hours, nearing a 52-week high. The spike came despite no new company news and follows the recent shutdown of its lead drug program and a strategic review. Market cap hovered around $10–11 million. Major shareholder Cambrian BioPharma filed to sell 21,222 shares the same day.
5 December 2025
··
Akanda Corp (AKAN) Stock Soars After Shareholder Vote: Reverse Merger, Mexico Towers and 2025–2030 Forecasts

Akanda Corp (AKAN) Stock Soars After Shareholder Vote: Reverse Merger, Mexico Towers and 2025–2030 Forecasts

Akanda Corp shares jumped about 45% in after-hours trading Thursday to $1.37 after shareholders approved major capital changes tied to its reverse merger with First Towers & Fiber Corp. The stock had closed regular trading at $0.95, with a market cap under $1 million. Akanda, once a medical cannabis firm, now owns a telecom infrastructure business in Mexico following the August merger.
5 December 2025
···
SciSparc (SPRC) Stock on December 5, 2025: Price Action, Quantum Data Deal, GERD Device Pivot and 2030 Forecast

SciSparc (SPRC) Stock on December 5, 2025: Price Action, Quantum Data Deal, GERD Device Pivot and 2030 Forecast

SciSparc Ltd. shares closed at $1.80 on December 5, 2025, after surging on volume above 10 million, following news of a quantum bio-data analytics deal via its NeuroThera subsidiary. The stock remains down over 70% in the past year and trades more than 95% below its 52-week high of $37.59, leaving the company with a market cap near $5.8 million.
5 December 2025
···
Jeffs’ Brands (JFBR) Soars on Scanary AI Security Deal: Can the Rally Last?

Jeffs’ Brands (JFBR) Soars on Scanary AI Security Deal: Can the Rally Last?

Jeffs’ Brands shares jumped 27% to $3.17 in early U.S. trading on December 5 after announcing a distribution deal for AI security scanners with Scanary Ltd. Volume surged past 20 million shares. The agreement gives Jeffs’ Brands exclusive rights in Canada, Germany, and the UAE for 24 months, with a $1 million payment to Scanary. Despite the rally, JFBR remains down over 90% year-to-date.
5 December 2025
·
United States Antimony (UAMY) Stock in December 2025: Pentagon Deal, Mining Push and What Analysts Expect Next

United States Antimony (UAMY) Stock in December 2025: Pentagon Deal, Mining Push and What Analysts Expect Next

United States Antimony shares jumped 15% to close at $6.12 on December 4, 2025, after securing a Pentagon contract worth up to $245 million and a new industrial supply deal. The stock has swung between $1.06 and $19.70 over the past year. Short interest stands near 13%. Trading remains volatile, with options activity and implied volatility near 140%.
5 December 2025
···
SEALSQ Corp (LAES) Stock: Quantum-Security High‑Flier After EeroQ Deal – Outlook as of December 5, 2025

SEALSQ Corp (LAES) Stock: Quantum-Security High‑Flier After EeroQ Deal – Outlook as of December 5, 2025

SEALSQ Corp (NASDAQ: LAES) shares jumped over 8% on December 4, closing near $5.08, capping a 1,000% gain over the past year. The Swiss semiconductor and security firm remains unprofitable and trades with a market cap near $0.9 billion. LAES stock has swung between $0.35 and $11.00 in the past 12 months. Volatility remains high, with daily moves often exceeding 10%.
5 December 2025
··
1 … 524 525 526 527 528 … 584
Go toTop